(E)-5-(2-bromovinyl)-2V -deoxyuridine (BVDU) is a potent inhibitor of herpes simplex virus type 1 (HSV-1) and varicella-zoster virus (VZV). Its mechanism of action is based on a specific conversion to its 5V -mono-and 5V -diphosphate derivative by HSV-1-and VZV-encoded thymidine kinase, and after further conversion to its 5V -triphosphate derivative, inhibition of the viral DNA polymerase and eventual incorporation into the viral DNA. Recently, a new structural class of bicyclic pyrimidine nucleoside analogues (designated BCNAs) with highly specific and selective anti-VZV activity in cell culture has been discovered. The compounds need a long alkyl or alkylaryl side-chain at the base moiety for pronounced biological activity. This property makes these compounds highly lipophilic. They are also endowed with fluorescent properties when exposed to light with short UV wavelength. In striking contrast to BVDU, the members of this class of compounds are active only against VZV, but not against any other virus, including the closely related HSV-1, HSV-2 and cytomegalovirus. The most active compounds inhibit VZV replication at subnanomolar concentrations and are not toxic at high micromolar concentrations. The compounds lose their antiviral activity against thymidine kinase (TK)-deficient VZV strains, pointing to a pivotal role of the viral TK in their activation (phosphorylation). Kinetic studies with purified enzymes revealed that the compounds were recognized by VZV TK as a substrate, but not by HSV-1 TK, nor by cytosolic or mitochondrial TK. VZV TK is able to phosphorylate the test compounds not only to their corresponding 5V -mono-but also to their 5V -diphosphate derivatives. These data may readily explain and rationalize the anti-VZV selectivity of the BCNAs. There is no clear-cut correlation between the antiviral potency of the compounds and their affinity for VZV TK, pointing to a different structure/activity relationship of the eventual antiviral target of these compounds. The compounds are stable in solution and, in contrast to BVDU, not susceptible to degradation by thymidine phosphorylase. The bicyclic pyrimidine nucleoside analogues represent an entirely new class of highly specific anti-VZV compounds that should be further pursued for clinical development. D
Introduction
Nucleoside analogues are well known as antiviral agents of biological interest and clinical utility, dominating the current treatment protocols for human viral infections. In particular, many nucleoside analogues with interesting biological properties have arisen by substitution at the 5-position of the uracil base in the 2V -deoxyuridine series [1] . The 5-(2-substituted-vinyl)-2V -deoxyuridines, in particular ((E)-5-(2-bromovinyl)-2V -deoxyuridine, BVDU, BrivudinR), have emerged as potent and selective inhibitors of herpes virus replication, particularly against HSV-1 (herpes simplex virus type 1) [2 -4] . 5-Alkynyl-2V -deoxyuridines have also been studied as potential antiviral agents, the parent 5-ethynyl derivative being a potent inhibitor of HSV-1, HSV-2 (herpes simplex virus type 2) and VV (vaccinia virus) [4] . However, this compound is also rather cytotoxic and its antiviral selectivity is low [4, 5] .
Herpes virus-encoded thymidine kinases (TK) often appear to be able to phosphorylate 5-substituted 2V -deoxy-uridines to their 5V -monophosphate derivatives [6] , and HSV-1 and VZV TK can even further convert the 5V -monophosphates to their 5V -diphosphate counterparts [7] [8] [9] . Most nucleoside analogues are further phosphorylated to the triphosphate derivatives by cellular enzymes, acting as inhibitors of virus-encoded DNA polymerase and/or as substrate analogues of these enzymes. Subsequent incorporation into viral DNA often represents the molecular basis of their antiviral action, although other targets such as virusspecified ribonucleotide reductase or even thymidylate synthase [10, 11] can be considered as a potential antiviral target for the phosphorylated nucleoside analogues as well. So far, all anti-VZV drugs and the majority of antiherpes agents are specifically activated (phosphorylated) by the virus-encoded thymidine kinase (TK) [2, 12] .
The structure of HSV-1 thymidine kinase was initially solved as a complex with gancyclovir [13] and with the natural substrate [14, 15] . More recently, complexes of HSV-1 TK with the antiherpes drug, acyclovir, [16] and a nonsubstrate inhibitor, to high resolution, have been published [17] , but VZV TK has not been crystallized and its threedimensional structure is unknown. However, the numerous detailed coordinate sets of HSV-1 TK should be of value in determining the structure of the VZV TK, as these two enzymes share 29% amino acid sequence identity [18] . Knowledge of the sites of binding of many ligands of interest should provide a framework for understanding the different substrate specificities of a range of TKs, including those from other herpes viruses.
The chemical synthesis of 5-alkynyl-2V -deoxyuridines involves the Pd-catalysed coupling of a terminal alkyne with a 5-substituted (usually 5-iodo) 2V -deoxyuridine [19, 20] . Whilst these methods give reasonable yields of the desired 5-alkynyl product, they always give variable quantities of a fluorescent by-product, characterized as the cyclised furano system [19 -21] . Such by-products apparently arise from the Pd (or Cu) catalysed cyclisation of the desired product and, indeed, can be prepared directly from the 5-alkynyl product upon copper treatment [19] . Previously, the only well-characterized examples of these furano nucleosides have been the parent compound (arising from cyclisation of 5-ethynyl-2V-deoxyuridine) [22 -24] and the n-butyl analogue [19] . Biological evaluation of these furano nucleosides has not been extensive to date but the parent compound was noted to be inactive against HSV-1, HSV-2, CMV and VZV [24] . Conventional wisdom would be that longer chain homologues would be similarly inactive.
We have recently discovered that certain long-chain substituted fluorescent furano bicyclic nucleoside analogues (designated BCNAs) are in fact potent and selective inhibitors of VZV replication in cell culture [25 -28] . This novel discovery has great potential for further exploration with the distinct possibility of new and improved drug discovery. The lead compound Cf1368 has-in cell culture-an anti-VZV activity, which is 100-fold more potent (EC 50 : 0.008 AM) than the current anti-VZV drug of choice (acyclovir: prodrug Valtrex) [25] . Moreover, we could not detect pronounced toxicity in cell culture. Surprisingly, this drug is active only against VZV, being completely inactive against any other virus, including the closely related HSV-1, HSV-2 and CMV. This pronounced antiviral selectivity is unprecedented.
This review describes the antiviral activities of the novel anti-VZV compounds, their structure -antiviral activity relationships and initial studies on their metabolic/enzymatic activation/inactivation pathways and the possible mechanism of antiviral action.
2. Structure-antiviral activity relationship of BCNAs against VZV replication in cell culture All BCNAs were evaluated for their inhibitory activity against VZV replication in human embryonic lung (HEL) cell cultures. Confluent HEL cells were grown in 96-well microtiter plates and innoculated with two wild-type (OKA and YS) and two thymidine kinase-deficient (07/1 and YS/ R) VZV strains at 100 plaque-forming units (PFU)/well. Antiviral activity of the test compounds was expressed as their 50% effective concentration (EC 50 ) or compound concentration required to reduce viral plaque formation by 50% compared with untreated controls. The 50% cytostatic concentration (CC 50 ) of the BCNAs was determined as the compound concentration required to inhibit exponentially growing HEL cell cultures by 50% (after counting the cell number using semiautomated Coulter counting).
BCNAs with a simple n-alkyl side-chain
Among those BCNAs that contain a simple alkyl sidechain on the bicyclic base ring, the optimal carbon chain length to display the most potent anti-VZV activity ranked between 8 and 10 (Table 1) . Indeed, the anti-VZV activity (EC 50 ) of these BCNAs was between 0.008 and 0.02 AM. At shorter or longer side-chain lengths, the antiviral activity markedly decreased by at least 1-2 orders of magnitude. When compared with BVDU and acyclovir (ACV), the most active anti-VZV BCNAs with a simple alkyl sidechain were virtually equally effective as the antiherpes virus drug BVDU (EC 50 : 0.005 AM) but at least 200-fold more active than ACV, the current drug of choice for the clinical treatment of VZV ( Table 1) . As for ACV and BVDU, the BCNAs fully lose antiviral activity against thymidine kinase-deficient VZV strains, pointing to a crucial role of the VZV-encoded TK in the activation (phosphorylation) of the BCNAs (Table 1) . Interestingly, none of the BCNAs listed in Table 1 were toxic to HEL cell proliferation at concentrations as high as 50-200 AM. As a result, the selectivity index (ratio CC 50 /EC 50 ) of the prototype compounds Cf1368, Cf1369 and Cf1676 is at least as high as 5000-20,000.
BCNAs with terminal alkyl unsaturation
A variety of BCNAs were synthesized containing a terminal alkyl unsaturation in the side-chain on the furanyl ring of the bicyclic base (Table 2) . Although a significant antiviral activity was recorded for the N-alkenyl-and Nalkynyl-BCNA derivatives, there is clearly a decreased antiviral efficiency of the N-alkenyl-, and even more of the N-alkynyl-BCNAs. Compared with the n-octyl-BCNA derivative (Cf1368), the N-octenyl-BCNAs lost f 10-fold antiviral activity, and the N-octynyl-BCNAs lost approximately 300-fold anti-VZV activity relative to the corresponding parental n-octyl-BCNA ( Table 2) . As found for the simple n-alkyl-substituted BCNAs, the terminally unsaturated n-alkenyl-and n-alkynyl-BCNAs completely lost antiviral activity against VZV TK À strains (data not shown).
BCNAs with a terminal halogen substitution in the nalkyl side-chain
When the terminal methyl group of the alkyl side-chain of the n-decyl-BCNA was replaced by a halogen, N-fluoro substitution virtually retained full antiviral efficacy, and the N-chloro-, N-bromo-and N-iodoalkyl-substituted BCNAs marginally lost antiviral efficacy (up to 2 -4-fold) ( Table 3) . There was no significant difference for the anti-VZV activities of the different N-halo-substituted alkyl-BCNAs.
BCNAs with an n-alkylaryl side-chain
In an attempt to restrict the conformational freedom of the alkyl side-chain of the prototype BCNAs Cf1368 and Cf1369, an aromatic ring system (phenyl) was introduced in the side-chain. In particular, a variety of p-alkylphenylBCNAs have been synthesized and evaluated for anti-VZV activity. As is clear from the antiviral data depicted in Table 4 , several members of the alkylaryl-BCNAs were exquisitely inhibitory against VZV replication. In particular, the n-pentylphenyl-and n-hexylphenyl-BCNAs were antivirally active at a concentration as low as 0.0001 -0.0005 AM, being endowed with a 10 -50-fold higher antiviral potency than the original prototype alkyl-BCNAs Cf1368 and Cf1369. Interestingly, longer and shorter alkyl groups at the para position on the phenyl group of the BCNAs led to lower antiviral activities (Table 4 ). In fact, shortening or lengthening the optimal pentylphenyl by only two to three carbons lead to a more than 100-fold lowering of the antiviral activity of the test compounds. The existence of an optimal chain length and the close dependence of the anti-VZV activity on the alkylaryl chain length have been also observed for the simple n-alkyl-substituted BCNAs. There appeared a strong correlation between the size (length) of the n-alkyl and n-alkylaryl moiety of the BCNAs on the one hand, and their optimal antiviral activity on the other (Fig. 1) . In fact, if the size of the phenyl group in the alkylaryl-BCNAs is considered as equivalent to f 4 methylene groups, the butylaryl-, pentylaryl-and hexylarylBCNAs and the octyl-, nonyl-and decyl-BCNAs represent members within each series of BCNAs with the highest antiviral potency (Tables 1 and 4 ; Fig. 1 ). It is striking, however, that the alkylaryl-BCNAs are invariably more potent than the n-alkyl-BCNAs. This may likely be related to the reduced conformational freedom of the alkylaryl sidechain relative to the long alkyl side-chain and, therefore, the alkylaryl-BCNAs may more optimally fit to their target enzyme than the more flexible n-alkyl-BCNAs. The pentylphenyl-BCNA represents the most potent anti-VZV compound hitherto reported. Due to lack of measurable cellular toxicity at 200 AM, its antiviral selectivity (ratio of CC 50 / EC 50 ) amounts to f 1,000,000, and its anti-VZV potency is 10 -30-fold more pronounced than BVDU, and f 10,000-fold more pronounced than ACV.
BCNAs with other heteroatoms in the bicyclic ring
The parent furano nucleus in the BCNAs has also been changed to a pyrro or thieno ring system, and the antiviral activities of these analogues compared for a series of nalkyl-substituted BCNAs (Table 5 ). Whereas substitution of the oxygen in the furano moiety by a nitrogen generally reduced the antiviral activity by 10-50-fold, the replacement of the oxygen by a sulfur atom resulted in most cases in a further 5 -10-fold increased anti-VZV activity. It is unclear whether the increased potency of [26] . Fig. 1 . Correlation between the anti-VZV activity of the simple n-alkyl-(E) (alkyl chain length R-1) and alkylphenyl-BCNAs (.) (alkyl chain length R-2) and the carbon side-chain length of the molecules. Assuming that the phenyl group in the alkylaryl-BCNA series accounts for four-carbon chain lengths, the correlation of optimal anti-VZV activity between both series of compounds fits very well. most thieno-BCNAs compared with the furano-BCNA is of benefit due to the higher cellular toxicity of the thienoBCNAs.
BCNAs with a different sugar moiety
Since the arabinosyl derivative of BVDU (designated BVaraU or SorivudineR) is at least as potent an antiherpetic agent as the deoxyriboside derivative [33] , and since it has also been reported that BVriboU is endowed with antiherpetic activity [34] , the sugar-modified arabinosyl and ribofuranosyl derivatives of the prototype n-octyl-BCNA (Cf1368) were synthesized and evaluated for their antiviral (VZV) potencies (Table 6 ). In marked contrast with BVaraU, the arabinosyl-BCNA was 300-fold less potent as an anti-VZV agent than its 2V -deoxy derivative, and the BCNA riboside was 3000-fold less potent in its anti-VZV activity. The free n-octyl-bicyclic base was devoid of any measurable anti-VZV activity (as also observed for BVU, the free base of BVDU).
Lipophilicity and water solubility of BCNAs
There is a stringent requirement of a relatively long alkyl or alkylphenyl side-chain at C-6 of the bicyclic furano or thieno pyrimidine ring of the BCNAs to display optimal anti-VZV activity. This property results in a relatively high lipophilicity of the compounds (represented by their calculated log P values (C log P) that range between 2.5 and 3.5). This striking observation has been noticed for the different series of BCNAs, including the n-alkylfurano (series 1), alkylphenylfurano (series 2), terminally unsaturated n-alkylfurano (series 3), n-alkylthieno (series 4) and n-alkylpyrro (series 5) BCNAs (Fig. 2) . The fact that a higher lipophilicity of BCNAs more or less corresponds with higher bulkiness of the side-chain, it is conceivable that an optimal C log P value for optimal anti-VZV activity reflects an optimal lipophilic interaction in the active site of the enzymes, or an optimal size of the side-chain that must fit in a lipophilic pocket of the particular enzymes. In an attempt to enhance the water solubility of the lead BCNAs, replacement of one of the methylene units in the n-decyl-BCNA chain by an oxygen (resulting in glycol/ether derivatives of the n-decyl-BCNA) resulted in a dramatically decreased C log P value of f 1.1 and a concomittantly decreased antiviral activity by 100-to >1000-fold [35] . Also, the terminally unsaturated nalkyl-BCNAs have a low (alkene) to dramatically lower (alkyne) C log P, and also a concomittant 50 -500-fold lower antiviral activity [29] . However, in both glycol/ether and terminal unsaturated n-alkyl-BCNA series, the overall size of the side-chain is virtually constant. Therefore, these observations suggest that the overall lipophilicity, rather than the size of the side-chain, is a predominant property [25, 31, 32] . b An accurate EC 50 value could not be calculated due to incomplete inhibition of VZV replication at higher drug concentrations and lack of a consistent dose -response curve. that eventually determines the antiviral potency of the test compounds. It may be somewhat surprising that a presumed lipophilic pocket to accommodate the rather bulky sidechain on the bicyclic pyrimidine ring of the BCNAs must be able to optimally adapt in at least two different enzymes (the activating (phosphorylating) VZV TK and the eventual antiviral target enzyme).
Although the high lipophilicity of the BCNAs results in a low to very low water solubility ( < 1 mg/l of the n-decyl-BCNA at room temperature), it is expected to lead to an efficient penetration of the BCNAs through cellular membranes and biological barriers such as the blood/brain barrier and the skin. This property may be advantageous for this novel class of anti-VZV compounds because uptake of the lipophilic BCNAs into cells and into biological compartments that may harvest the virus, may be facilitated by the higher lipophilicity of these drugs.
Anabolic conversion of BCNAs to their phosphorylated derivatives
Since the BCNAs listed in Tables 1 -6 markedly lose antiviral activity against VZV strains that are deficient in the virus-encoded thymidine kinase, it can be anticipated that the compounds need to be activated (phosphorylated) by the viral TK before they inhibit their antiviral targets.
A variety of BCNAs, in particular the series of nalkylphenyl-BCNAs, were evaluated for their inhibitory effect against 1 AM [ 3 H]dThd phosphorylation by VZV TK, HSV-1 TK, HSV-2 TK, TK-1 and TK-2 (Table 7) . Only VZV TK-catalysed [ 3 H]dThd phosphorylation was inhibited by the BCNAs, reflecting their affinity for VZV TK, likely a competitive inhibition of the enzyme reaction with the natural substrate. It also became obvious from these data that there was no close correlation between affinity for VZV TK and the eventual anti-VZV activity of the BCNAs. These observations make it clear that the SARs of the activating (phosphorylating) enzyme are different from those of the (antiviral) target enzyme.
Cf1368 and Cf1369 were directly investigated as substrates for purified VZV TK, and also for purified HSV-1 and HSV-2 TK [36] . Interestingly, only VZV TK measurably converted the compounds to their 5V-monophosphate derivatives. By contrast, BVDU was easily converted to its 5V -monophosphate derivative by VZV TK, and also by HSV-1 TK, and HSV-2 TK (and mitochondrial TK) [6] . BVDU is not measurably phosphorylated by cytosolic TK- (Table 1) . Series 2: n-alkylphenyl-BCNAs (Table 4) . Series 3: terminal unsaturated n-alkyl-BCNAs (Table 2 ). Series 4: thienopyrimidine BCNAs (Table 5 ). Series 5: pyrrolopyrimidine BCNAs (Table 5) . Ethyl >500 >500 >500 >500 13 Cf1698
Propyl >500 >500 >500 >500 25 Cf1744
Butyl >500 >500 >500 >500 4.7 Cf1743
Pentyl >500 >500 >500 >500 3.9 Cf1742
Hexyl >500 >500 >500 >500 4.5 Cf1712
Heptyl >500 >500 >500 3540 Cf1711
Octyl >500 >500 >500 >5000 Cf1368 >500 >500 >5000 >5000 37 BVDU >1000 0.34 2.9 5.6 1.5 a 50% Inhibitory concentration or compound concentration required to inhibit nucleoside kinase-catalysed phosphorylation of 1 AM [CH 3 -3 H]dThd by 50%.
1. Compared with BVDU, the BCNAs had a much higher V max but also a much higher K m , for VZV TK. The exact V max values for the BCNAs could not be measured due to limited solubility of the compounds, in the millimolar concentration range.
We also evaluated the 5V -monophosphate derivatives of Cf1368 (Cf1928) and Cf1369 (Cf1602) as substrates for the dTMP kinase activity associated with VZV TK and HSV-1 TK [36] . Again, both enzymes displayed a striking discrimination between BVDU-MP and the BCNA-MPs. Whereas BVDU-MP was efficiently converted by both enzymes to its 5V-diphosphate derivative (BVDU-DP), only VZV TK, but not HSV-1 TK, was able to recognize the BCNA-MPs as efficient substrates for phosphorylation. Cellular dTMP kinase was also unable to recognise the BCNA-monophosphates. Thus, it became clear that the BCNAs are selectively phosphorylated to their 5V -diphosphates by the two successive enzyme activities of VZV TK (thymidine kinase and dTMP kinase), while they are not recognized by the TK/ dTMP kinase activity of HSV-1 or the cytosol under similar experimental conditions (Fig. 3a) . In this respect, the BCNAs strikingly differ from BVDU ( Fig. 3b) and our observations provide an explanation for the unprecedented inhibitory specificity of the BCNAs for VZV.
Interestingly, when human erythrocyte NDP kinase was added to a reaction mixture containing BVDU or BCNAs and VZV TK, a considerable amount of BVDU-TP was formed, whereas no trace of BCNA-TP could be detected [36] . Although it cannot be excluded that the BCNA-DPs can be recognized by other NDP kinase isoenzymes or by other (less obvious) cellular enzymes, our observations may indicate that the mechanism of anti-VZV activity of the novel class of BCNAs may be entirely different from that of BVDU (being a competitive inhibitor of viral DNA polymerase and incorporated into viral DNA upon conversion to the 5V -triphosphate derivative). This is being further studied in our laboratories.
Catabolic conversion of BCNAs by cellular enzymes
Nucleoside analogues may be prone to catabolic hydrolysis by several enzymes (i.e., purine nucleoside phosphorylase (PNPase), thymidine phosphorylase (TPase), uridine phosphorylase (UPase)). In particular, 2V -deoxyribonucleoside analogues such as BVDU are good substrates for thymidine phosphorylase, which efficiently converts BVDU to its free (antivirally inactive) base BVU [37] . Crystals of E. coli TPase complexed with the natural substrate dThd [38] demonstrate that the hydrogen at the N(3) position of the pyrimidine ring forms a hydrogen bridge with amino acid Ser-186 of TPase, and the carbonyl group at position 4 of the pyrimidine ring forms a close interaction with amino acid Arg-171. Interestingly, the BCNAs have no free carbonyl at the same position in the pyrimidine ring, but more importantly, due to the fused ring system, the bicyclic base BCNA-DP is not a substrate for E. coli or human erythrocyte nucleoside diphosphate kinase (NDP-K). It is not known whether other cellular enzymes may recognize BCNA-DP as a substrate to be converted to BCNA-TP. BCNA is not measurably hydrolysed by E. coli or human erythrocyte TPase to its free base [39] . The free bicyclic base does not inhibit dihydropyrimidine dehydrogenase (DPD) [39] . (b) Metabolic fate of BVDU. BVDU is converted to its 5V -monophosphate derivative by the TKs encoded by HSV-1, HSV-2 and VZV, and by mitochondrial TK-2, but not by cytosolic TK-1. BVDU-MP inhibits thymidylate synthase (TS). BVDU-MP is converted to its 5V -diphosphate derivative by the TKs encoded by HSV-1 and VZV TK, but not by HSV-2 TK or cytosolic dTMP kinase (dTMP-K). BVDU-DP is converted by NDP kinase (NDP-K) to BVDU-TP. The latter metabolite is recognized by cellular and herpetic DNA polymerases, and incorporated into viral and cellular DNA. BVDU is hydrolysed by thymidine phosphorylase (TPase) to its free base BVU, which in turn is a potent inhibitor of dihydropyrimidine dehydrogenase (DPD).
of the BCNAs has no hydrogen available on the original N(3) position of the pyrimidine ring. Therefore, it could be anticipated that TPase would not efficiently recognize the BCNAs as substrates for cleavage to the free base. Indeed, when the BCNAs were exposed to both E. coli or human TPase, no hydrolysis to the free base could be detected under conditions where BVDU and dThd were markedly converted to their free bases BVU and Thy, respectively [39] . It follows that-in contrast to BVDU-the BCNAs do not act as substrates for the catabolic TPase and thus, should be rather stable in biological systems (i.e., plasma). Indeed, preliminary experiments in which Cf1368 was administered both intravenously or perorally, no indication of release of the free base was obtained, and a pronounced appearance of unaltered drug in plasma upon oral administration was found (unpublished data).
Conclusions
The novel class of BCNAs represents the most potent and selective anti-VZV compounds hitherto described. The selectivity is at least partially based on a specific ability of VZV TK to convert the compounds to their 5V-mono-and 5V -diphosphate derivatives. Although the BCNAs have a number of interesting properties that make them prime candidates for further development to the clinic, their molecular mechanism of action remains to be resolved and is currently the subject of further investigations.
